Gene
NTRK1
NTRK1 is a gene biomarker in the evidence tier "FDA companion diagnostic". This page lists evidence by type: FDA companion diagnostic assertions (4), Assay-provider ledger (63), Actionable biomarkers (6), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
FDA companion diagnostic
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention NTRK1. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with a planned future start and 3 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 1 dated before 1990 and 12 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 12 of 8,738 | 0.14% | not measured | |
| 2025 | 9 of 8,875 | 0.10% | not measured | |
| 2024 | 7 of 8,597 | 0.08% | not measured | |
| 2023 | 10 of 8,275 | 0.12% | 21 of 11,460 | 0.18% |
| 2022 | 10 of 8,285 | 0.12% | 33 of 13,598 | 0.24% |
| 2021 | 14 of 8,692 | 0.16% | 33 of 15,045 | 0.22% |
| 2020 | 7 of 7,640 | 0.09% | 33 of 14,459 | 0.23% |
| 2019 | 5 of 7,300 | 0.07% | 38 of 12,159 | 0.31% |
| 2018 | 4 of 6,927 | 0.06% | 23 of 11,854 | 0.19% |
| 2017 | 5 of 6,558 | 0.08% | 20 of 11,595 | 0.17% |
Showing 10 of 37 years.
FDA companion diagnostic assertions (4)
Shown in this order: most recent decision first.
| Diagnostic | Source biomarker wording | Manufacturer | Indication | Decision date |
|---|---|---|---|---|
| TruSight Oncology Comprehensive | NTRK1 | Illumina, Inc. | Solid Tumors | 2024-08-21 |
| FoundationOne Liquid CDx | NTRK1 | Foundation Medicine, Inc. | Solid Tumors | 2022-12-22 |
| FoundationOne CDx | NTRK1 | Foundation Medicine, Inc. | Solid Tumors | 2022-06-07 |
| FoundationOne CDx | NTRK1 | Foundation Medicine, Inc. | Solid Tumors | 2020-10-23 |
Assay-provider ledger (63)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Horizon Diagnostics | Reagent supplier | Clinical validationAnalytical validation | 1 | October 17, 2025 |
| ROCHE DIAGNOSTICS | Context dependent | Clinical validationAnalytical validation | 1 | October 17, 2025 |
| THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) | Reagent supplier | Clinical validationAnalytical validation | 4 | October 17, 2025 |
| OC Medicina de Precisão Oncoclínicas&Co (Oncoclínicas Medicina de Precisão, OCPM) | Diagnostic provider | Clinical validationAnalytical validation | 1 | July 26, 2025 |
| PlexBio (Taiwan) | Diagnostic provider | Clinical validationAnalytical validation | 1 | July 26, 2025 |
Showing 5 of 63 assay-provider companies.
Actionable biomarkers (6)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| NTRK1 (G595R,G667C) | Entrectinib | responsive | colorectal adenocarcinoma | Cancer Genome Interpreter |
| NTRK1 fusion | Entrectinib | response-associated | colorectal adenocarcinoma | Cancer Genome Interpreter |
| NTRK1 fusion | Crizotinib | response-associated | lung adenocarcinoma | Cancer Genome Interpreter |
| NTRK1 fusion | Pan-tk Inhibitors | response-associated | lung adenocarcinoma | Cancer Genome Interpreter |
| NTRK1 fusion | Pan-tkr Inhibitors | response-associated | No disease recorded | Cancer Genome Interpreter |
Showing 5 of 6 actionable-biomarker assertions.
Trial mentions (106)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT07405190 | Trial eligibility (AACT) |
| NCT07122882 | Trial eligibility (AACT) |
| NCT03452774 | Trial eligibility (AACT) |
| NCT05783323 | Trial eligibility (AACT) |
| NCT05236257 | Trial eligibility (AACT) |
Showing 5 of 106 trial mentions.
Target-disease associations (503)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Aganglionic megacolon | phenotype | Variant curation (ClinVar / EVA) |
| Alzheimer disease | nervous system disease | crispr screen |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Ampulla of Vater Carcinoma | cancer or benign tumor | Cancer Gene Census |
| Aniridia - ptosis - intellectual disability - familial obesity | disorder of visual system | Mouse knockout (IMPC) |
Showing 5 of 503 associations.
Vendor sourcing (308)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | Intron variant: previously reported to alter splicing and result in a loss of normal protein fucnction through nonsense-mediated decay (NMD) or protein trunc... | View ClinVar record SCV002012158.1 |
| AP Biosciences Inc. | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Participants who have histologically or cytologically confirmed diagnosis of relapsed or refractory, locally unresectable advanced or metastatic NSCL... | View trial NCT05473156 |
| AP Biosciences Inc. | Trial sponsor | Mentioned in trial textTrial free-text mention | NTRK1 | View trial NCT05473156 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The NTRK1 c.865C>A; p.Gln289Lys variant (rs137979116), to our knowledge, is not reported in the medical literature but is reported in ClinVar (Variation ID: ... | View ClinVar record SCV001472839.4 |
| Abbisko Therapeutics Co., Ltd. (China) | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : 1. Known allergy or hypersensitivity to any component of the investigational product 2. (For backfill cohorts and expansion part) Patients who were previo... | View trial NCT07417189 |
Showing 5 of 308 sourcing records.
Trial-cited literature (334)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Precision Medicine Program in Chinese Pediatric Patients With Sarcoma. | JCO precision oncology | 2026 | 0 |
| Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric <i>NTRK</i> Fusion-Positive Solid Tumors (Children's Oncology Group ADVL1823). | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | 22 |
| Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions. | European journal of cancer (Oxford, England : 1990) | 2025 | 18 |
| Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | 18 |
| Larotrectinib Compared With Real-World Non-Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer. | JCO precision oncology | 2025 | 2 |
Showing 5 of 334 papers.
Protein variant mentions (42)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A758T | 2 | 2015 to 2016 | PMID 26467025, PMID 25741868 |
| p.D674Y | 1 | 2015 | PMID 25741868 |
| p.E172K | 1 | 2015 | PMID 25741868 |
| p.E492K | 1 | 2015 | PMID 25741868 |
| p.E707K | 1 | 2015 | PMID 25741868 |
Showing 5 of 42 variants.
Literature-extracted relations (94)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Amitriptyline | Chemical | negative_correlate |
The tricyclic antidepressant amitriptyline is cytotoxic to HTB114 human leiomyosarcoma and induces p75(NTR)-dependent apoptosis. | 2013 |
| Neoplasms | Disease | associate |
Molecularly driven therapies in the treatment of primary brain tumors. | 2025 |
| Neoplasms | Disease | associate |
Larotrectinib Compared With Real-World Non-Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer. | 2025 |
| Neoplasms | Disease | associate |
Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors. | 2025 |
| Sarcoma | Disease | associate |
Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors. | 2025 |
Showing 5 of 94 relation assertions.
Organizations publishing (378)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 29 | 2016 to 2025 |
| Harvard Medical School | Academic | 21 | 2009 to 2023 |
| Mass General Brigham | Hospital | 20 | 2015 to 2023 |
| The University of Texas System | Academic | 15 | 2010 to 2023 |
| Stanford University | Academic | 11 | 2017 to 2023 |
Showing 5 of 378 organizations.
Where NTRK1 appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
412 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda biomarker qualification projects and human sample screening reference.